These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11221957)

  • 1. The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin.
    Fujiwara K; Yamauchi H; Suzuki S; Ishikawa H; Tanaka Y; Fujiwara M; Kohno I
    Cancer Chemother Pharmacol; 2001; 47(1):22-6. PubMed ID: 11221957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of carboplatin administered in combination with paclitaxel.
    van Warmerdam LJ; Huizing MT; Giaccone G; Postmus PE; ten Bokkel Huinink WW; van Zandwijk N; Koolen MG; Helmerhorst TJ; van der Vijgh WJ; Veenhof CH; Beijnen JH
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-97-S2-104. PubMed ID: 9045347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
    Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of relative factors of bone marrow suppression after chemotherapy with carboplatin and paclitaxel on the patients with ovarian cancer].
    Ding D; Kong WM
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):188-92. PubMed ID: 21575452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.
    Reyno LM; Egorin MJ; Canetta RM; Jodrell DI; Swenerton KD; Pater JL; Burroughs JN; Novak MJ; Sridhara R
    J Clin Oncol; 1993 Jun; 11(6):1156-64. PubMed ID: 8501502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study.
    ten Bokkel Huinink W; Veenhof C; Huizing M; Rodenhuis S; Helmerhorst T; Dubbelman R; Dalesio O; Beijnen J; Winograd B
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-31-S2-33. PubMed ID: 9045333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating the relationship between serum thrombopoietin kinetics and the platelet-sparing effect: A clinical pharmacological evaluation of combined paclitaxel and carboplatin in patients with non-small cell lung cancer.
    Daga H; Isobe T; Miyazaki M; Fujitaka K; Kondo K; Kohno N
    Oncol Rep; 2004 Jun; 11(6):1225-31. PubMed ID: 15138560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer.
    Watanabe M; Aoki Y; Tomita M; Sato T; Takaki Y; Kato N; Kikuchi M; Kase H; Tanaka K
    Gynecol Oncol; 2002 Feb; 84(2):335-8. PubMed ID: 11812097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.
    Calvert AH; Boddy A; Bailey NP; Siddiqui N; Humphreys A; Hughes A; Robson L; Gumbrell L; Thomas H; Chapman F
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):91-8; discussion 99-100. PubMed ID: 7481870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study on hematological effects of carboplatin plus cyclophosphamide and carboplatin plus paclitaxel chemotherapy for the first line treatment of epithelial ovarian cancer.
    Vapattanawong P
    J Med Assoc Thai; 2006 Sep; 89(9):1357-61. PubMed ID: 17100369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.
    Bos AM; De Vos FY; de Vries EG; Beijnen JH; Rosing H; Mourits MJ; van der Zee AG; Gietema JA; Willemse PH
    Eur J Cancer; 2005 Mar; 41(4):539-48. PubMed ID: 15737558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.
    van der Burg ME; Vergote I; Onstenk W; Boere IA; Leunen K; van Montfort CA; van Doorn HC
    Eur J Cancer; 2013 Apr; 49(6):1254-63. PubMed ID: 23276720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer.
    Sharma R; Graham J; Blagden S; Gabra H
    BMC Cancer; 2011 Jul; 11():289. PubMed ID: 21745358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin?
    Higgins RV; Naumann RW; Gardner J; Hall JB
    Gynecol Oncol; 1999 Dec; 75(3):464-7. PubMed ID: 10600308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.
    Meerpohl HG; du Bois A; Luck HJ; Kühnle H; Möbus V; Kreienberg R; Bauknecht T; Köchli O; Bochtler H; Diergarten K
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-17-S2-22. PubMed ID: 9045330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.